What are the opening hours?

Monday 9am - 5pm Tuesday 9am - 5pm Wednesday 9am - 5pm Thursday 9am - 5pm Friday 9am - 5pm

Telix Pharmaceuticals Limited

Home
Australia
Melbourne, VIC
Telix Pharmaceuticals Limited

Directions Website

Listed on the ASX and Nasdaq under the ticker TLX. You are encouraged to report negative side effects of prescription drugs to the FDA.

Telix is a global biopharmaceutical company focused on developing and commercializing radiopharmaceuticals to address significant unmet medical need in oncology and rare diseases. Telix is a clinical-stage biopharmaceutical company developing diagnostic and therapeutic products using Molecularly Targeted Radiation (MTR). Telix is headquartered in Melbourne, Australia with international operations in Belgium, Japan, and the United States. Telix is developing a portfolio of clinical-stage products that address significant unmet medical needs in oncology and rare diseases. Visit MedWatch at www.fda.gov/medwatch or call 1-800-FDA-1088. You may also report adverse reactions to Telix by calling 1-844-455-8638 or emailing [email protected]. Please see full Illuccix Prescribing Information:https://illuccixhcp.com/wp-content/uploads/illuccix-prescribing-information.pdf

01/11/2026

An important milestone for prostate cancer care in Australia.

From November 1, Australian men with recurrent prostate cancer now have expanded Medicare-funded access to PSMA-PET/CT imaging, with the previous limit of two scans per lifetime replaced by access to annual scans.

We welcome this important step towards improving access to advanced imaging for Australian men living with prostate cancer.

As PSMA-PET/CT has become an established standard of care in the management of recurrent prostate cancer, this change reflects the need for ongoing access to this important imaging modality.

Thanks to the Prostate Cancer Foundation of Australia (PCFA) for its advocacy in helping bring about this change.

Learn more: https://www.pcfa.org.au/news-media/news/federal-government-expands-medicare-access-to-psma-pet-scans-for-prostate-cancer/

29/10/2026

Telix today announces a General Meeting of shareholders, relating to the proposed merger with ITM Isotope Technologies Munich SE (ITM), a global leader in radioisotope production and radiopharmaceutical development.

The General Meeting will be held in Melbourne, Australia and online on Tuesday, December 1, 2026 at 10:00 a.m. (Melbourne time).

The shareholder pack, comprising the Notice of Meeting, Proxy Form and Online Guide can be found here: https://telixpharma.com/news-views/telix-notice-of-general-meeting/

28/10/2026

Join us next Wednesday, November 4, for Telix’s 2026 Capital Markets Day in Melbourne.

Members of the Telix leadership team and key opinion leaders will share the latest scientific, clinical and strategic developments across our commercial portfolio and industry-leading theranostic pipeline.

Institutional investors and analysts are invited to join us in-person, with the event also webcast live and available afterwards on demand.

Shareholders can learn more and register here: https://telixpharma.com/news-views/telix-to-host-capital-markets-day-in-melbourne-on-november-4-2026/

21/10/2026

And the winner of the 2026 EANM Sanjiv Sam Gambhir Award is… Caner Civan from the Universitätsmedizin Essen!

Congratulations Caner on your achievement, and best of luck for your visitorship at Stanford University.

A big thank you to the European Association of Nuclear Medicine (EANM) for the opportunity to support the next generation of scientists and physicians through this exciting award, in memory of a pioneer in nuclear medicine and molecular imaging.

Thank you to the brilliant hosts, Francesca Serani and Joshua James M. and jury members, Andrei Iagaru, Burger Irene, Simone Dalm and Riccardo Laudicella

20/10/2026

Telix today provides a market update for Q3 2026, reporting unaudited Group revenue of US$245 million, up 19% year-on-year.

Precision Medicine revenue increased 30% year-on-year to US$201 million, driven by continued strong demand for Illuccix® and Gozellix®.

The quarter also delivered significant milestones, including:

🔵 U.S. FDA approval of Pixclara® for glioma imaging, and first commercial doses.

🔵 Completion of enrollment in the Phase 3 BiPASS® study, evaluating 68Ga-PSMA-11 PET imaging in the pre-biopsy prostate cancer setting.

🔵 Announcement of a proposed merger with ITM, bringing together complementary therapeutic pipelines, isotope production and manufacturing capabilities.

Read the full announcement here: https://telixpharma.com/news-views/telix-reports-third-quarter-2026-financial-performance/

Illuccix® (kit for the preparation of gallium Ga 68 gozetotide injection) has been approved by the FDA and in multiple markets globally. Gozellix® (kit for the preparation of gallium Ga 68 gozetotide injection) and Pixclara® (floretyrosine F 18) have been approved by the FDA.

19/10/2026

Telix has announced a collaboration with Ekalia, a joint venture between IBA and Framatome, to advance scalable U.S. production of astatine-211 (²¹¹At), a promising radioisotope for targeted alpha therapy.

The collaboration will establish a dedicated U.S. source of ²¹¹At, with the first specialized alpha-beam cyclotron to be installed at our RLS Radiopharmacies site near Philadelphia, Pennsylvania.

This will support Telix’s investigational alpha therapy pipeline, provide isotope access for third-party academic and industry programs, and further strengthen our vertically integrated radiopharmaceutical supply chain.

Read more: https://telixpharma.com/news-views/telix-and-ekalia-to-collaborate-on-astatine-211-production-in-the-u-s/

18/10/2026

📢 Today’s the day!

A final reminder to join our EANM sponsored symposium at 13:15 today in Hall F2, “The Future Doesn't Wait: The Next Era of Theranostics in Urologic Oncology.”

Chaired by Prof. Dr. Jeremie Calais, the symposium will bring together leading experts to explore the evolving role of theranostics in prostate cancer, from where PSMA-PET is heading and how it can be optimized in clinical practice, to current challenges and opportunities in targeted radionuclide therapy, including learnings from the OPTIMAL series of studies.

Hear from Prof. Dr. Ken Herrmann, Prof. Dr. Munir Ghesani, Prof. Dr. Daniela Oprea-Lager and Prof. Dr. Louise Emmett as they discuss what the next era of urologic oncology could look like.

Explore the full symposium details below and visit our website for more on Telix’s presence at

https://telixpharma.com/news-views/telix-highlights-pivotal-trials-in-prostate-brain-and-renal-cancers-and-next-generation-theranostics-at-eanm/

12/10/2026

In addition to consistently high image quality, 68Ga-PSMA-11 PET offers practical advantages.

In this second episode of Radiopharma Unpacked, Dr. Paul Yonover explains how a same-day workflow suited to high volume services has helped establish gallium-based PSMA-PET as a standard of care in prostate cancer imaging.

Watch the full episode here: https://bit.ly/47VCQ69

12/10/2026

Thank you to Krystyna and husband Ted for describing her courageous battle with brain cancer and what an approved imaging agent for glioma means for patients and their families.

We’re grateful to them and to our partners at IU Health for helping raise awareness.

Video credit: IU Health Social Media

09/10/2026

Rounding out our Nuclear Medicine & Molecular Imaging Week spotlight is Dr. Neha Vapiwala.

Her career sits at the intersection of radiation oncology and nuclear medicine, two specialties that increasingly depend on each other, and on people willing to build the bridge between them.

Thank you to Dr. Vapiwala, Dr. Esfahani, Dr. Corzo and to everyone advancing theranostics for the benefit of patients.

Inspired by their stories? Explore careers at Telix: https://telixpharma.com/careers/

Address

55 Flemington Road, North
Melbourne, VIC
3051

Opening Hours

Monday	9am - 5pm
Tuesday	9am - 5pm
Wednesday	9am - 5pm
Thursday	9am - 5pm
Friday	9am - 5pm

Website

http://www.telixpharma.com/

Alerts

Be the first to know and let us send you an email when Telix Pharmaceuticals Limited posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.